Indeed, vismodegib, a SMO-specific inhibitor, is a promising therapeutic approach for cancer treatment in BCC and medulloblastoma [15, 16], but the effectiveness remains to be determined in GBM [17]. This evidence concerns the gene SMO and skin basal cell carcinoma.